Novartis Ends BioArctic BrainTransporter Deal, Keeps $30M Upfront
STOCKHOLM – November 02, 2026 -- BioArctic AB will keep the full USD 30 million upfront payment from Novartis Pharma AG after Novartis terminated their Option, Collaboration and License Agreement, the Nasdaq Stockholm-listed company (BIOA B) announced.
Novartis drops the program, not the technology
The agreement was signed in August 2025. It covered a potential new treatment combining BioArctic's proprietary BrainTransporter technology with an undisclosed Novartis proprietary antibody. Novartis notified BioArctic that it decided to discontinue the program. According to BioArctic, the decision is unrelated to the BrainTransporter technology.
BioArctic books the remaining upfront payment as 2026 revenue
Because of the termination, BioArctic will recognize the remaining unrecognized portion of the USD 30 million upfront payment as revenue in 2026. The company did not disclose the size of that portion.